BerandaGRTSQ • OTCMKTS
add
Gritstone bio Inc
Tutup sebelumnya
$0,021
Rentang hari
$0,018 - $0,027
Rentang tahun
$0,013 - $3,17
Kapitalisasi pasar
2,84Â jt USD
Volume Rata-Rata
35,84Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
OTCMKTS
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 921,00Â rb | -52,89% |
Biaya operasional | 7,70Â jt | 14,62% |
Laba bersih | -23,40Â jt | 33,64% |
Margin laba bersih | -2,54Â rb | -40,86% |
Penghasilan per saham | -0,16 | 48,39% |
EBITDA | -25,98Â jt | 23,17% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 55,71Â jt | -51,36% |
Total aset | 142,54Â jt | -35,97% |
Total liabilitas | 120,35Â jt | 6,45% |
Total ekuitas | 22,19 jt | — |
Saham yang beredar | 118,11 jt | — |
Harga terhadap nilai buku | 0,11 | — |
Tingkat pengembalian aset | -49,31% | — |
Tingkat pengembalian modal | -57,02% | — |
Arus Kas
Perubahan kas bersih
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -23,40Â jt | 33,64% |
Kas dari operasi | -26,81Â jt | 13,41% |
Kas dari investasi | -885,00Â rb | -103,60% |
Kas dari pembiayaan | 35,63Â jt | 3.403,74% |
Perubahan kas bersih | 7,94Â jt | 248,24% |
Arus kas bebas | -14,40Â jt | 32,03% |
Tentang
Gritstone bio is a clinical-stage American biotechnology company which develops cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., and is based in Emeryville, California.
In September 2021 it raised $55.0 million from the sale of 5,000,000 shares.
It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHCR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021. This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes. Prof. Andrew Ustianowski is the study’s chief investigator.
On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA vaccine against SARS-CoV-2 in non-human primate models. Wikipedia
Didirikan
Agu 2015
Kantor pusat
Situs
Karyawan
231